GlassScriptPhysician profile
Steven A Tenenbaum
NPI 1023126661
$3,899.85
in general payments reported to CMS, 2019-2025
34 companies · $336 in 2025
The $336 reported for 2025 was more than what 78% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $192 · 2021: $449 · 2022: $864 · 2023: $938 · 2024: $637 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.84 | 2021-2024 | Ubrelvy, Qulipta |
| Abbott Laboratories | $455.10 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $446.06 | 2019-2025 | Repatha |
| Lilly USA, LLC | $395.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $257.00 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.67 | 2019-2022 | |
| Therapeuticsmd, INC. | $148.27 | 2019-2020 | |
| Eisai INC. | $144.97 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $137.53 | 2022-2024 | Quviviq |
| Mayne Pharma Commercial LLC | $117.60 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.51 | 2021 | |
| Intuitive Surgical, INC. | $111.35 | 2019-2022 | |
| Sanofi Pasteur INC. | $110.42 | 2023 | |
| Corcept Therapeutics | $102.40 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $87.89 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $72.59 | 2023-2025 | Adthyza, Horizant, Azmiro |
| Gilead Sciences, INC. | $70.04 | 2023 | Epclusa |
| Novartis Pharmaceuticals Corporation | $67.14 | 2020-2023 | |
| Mannkind Corporation | $54.57 | 2022 | |
| Acerus Pharmaceuticals Corporation | $40.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $36.24 | 2021 | |
| Pfizer INC. | $30.66 | 2021 | |
| Antares Pharma, INC. | $28.84 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Bioventus LLC | $26.62 | 2023 | Supartz Fx Sodium Hyaluronate |
| Dexcom, INC. | $25.05 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $18.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.27 | 2019 | |
| Heartflow, INC. | $17.39 | 2022 | |
| Phadia US INC. | $17.01 | 2023 | Immunocap |
| Exact Sciences Corporation | $15.60 | 2023 | Cologuard Collection Kit |
| Alk-Abello, INC | $13.68 | 2024 | Grastek, Odactra, Ragwitek |
| Janssen Pharmaceuticals, INC | $13.10 | 2021 | |
| Vertiflex, INC. | $12.80 | 2019 | |
| Bausch Health US, LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Tenenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.